Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors
Starting soon
Conditions studied: Renal Cell Carcinoma (Kidney Cancer)
In brief
This is a research study aiming to better understand a type of kidney cancer called Renal Cell Carcinoma (RCC). Doctors have observed that inside some larger RCC tumors, there are multiple smaller nodules. This study wants to find out if these nodules are different from each other and how they might be related. To do this, researchers will study tumor tissue samples from 10 patients with RCC who are having surgery. From each tumor, several nodules will be analyzed using advanced laboratory techniques. These techniques will create very detailed maps of the genes and cells within each nodule. At the same time, tiny 3D tumor models (called microtumors) will be grown from these samples in the lab to test how they respond to different cancer drugs. The main goal is to combine these two types of information to see how the differences in genes and cells between nodules might explain why some tumors stop responding to treatment (become resistant). We hope this study will lead to a deeper understanding of how RCC grows and spreads, and help find new ways to diagnose and treat it in the future.
Key facts
- Study ID
- NCT07351266
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 10
- Starts
- 2026-01-25
- Expected to finish
- 2030-01-25
- Last updated by the study team
- 2026-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed renal cell carcinoma with regional lymph node metastasis.
- Primary tumor with a maximum diameter ≥ 7 cm.
- Tumor exhibits a multinodular distribution pattern on cross-section (assessed via intraoperative or postoperative gross specimen).
- Age > 18 years.
- Ability to understand the study and voluntarily provide written informed consent.
You may not qualify if…
- Presence of distant metastasis (M1 stage).
- Prior receipt of any targeted therapy or immunotherapy for renal cell carcinoma before surgery.
- History of other active malignancies besides RCC (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
- Any psychiatric, neurological, or legal condition that may compromise the ability to understand the informed consent or to comply with study procedures.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.